Nanologica AB (NICA)
Free
No email, no account, no signup.
Pulling latest news for Nanologica AB…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report – Signal
HOLD
Sentiment
6/10
Risk
8/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Buy express analysis –
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Sentiment has improved to weak/near-neutral after the Q1 release and a strengthened balance sheet, but investors remain cautious as the profit uplift is largely acquisition accounting and integration/underlying cash generation still needs to be proven.
Exchange
Nasdaq Stockholm
Type
Biotech
Market Cap
$4M
Market sentiment
Sentiment has improved to weak/near-neutral after the Q1 release and a strengthened balance sheet, but investors remain cautious as the profit uplift is largely acquisition accounting and integration/underlying cash generation still needs to be proven.
Why HOLD ?
Near-term financing risk has eased following completed equity issues and debt-to-equity conversion, alongside a much stronger cash position. However, Q1 profitability is largely a one-off acquisition effect, so the case now hinges on integration execution, CDMO margins, and sustainable revenue growth.
- Wait/hold until the company delivers 1–2 quarters of stable underlying operating performance and cash flow from the combined CDMO platform. Watch Q2 (27 Aug) for organic trends, integration costs, and order intake.
Recent News
- Since the last analysis: On 1 June 2026, CFO Eva Österman announced she will leave Nanologica, remaining until 31 Aug 2026; the search for a successor has started. Otherwise, no new reports, financings, or major operational updates have been communicated; attention remains on integration and underlying profitability after Q1, which was materially affected by acquisition-related one-offs. Next report is Q2 on 27 Aug 2026.
Catalysts
27 Aug 2026 — Q2 2026: first quarter with clearer integration read-through
Dilution Risk
Assessment: High
Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Nanologica AB – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
Full analysis at introductory pricing — 7-day money-back guarantee.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.